The Mechanism of Extracellular Vesicles Containing Mitochondrial DNA in

Status Not yet recruiting

Clinical Trial Summary

The acute respiratory distress syndrome (ARDS) remains a common and morbid complication of critical illness. Sepsis contribute to a lot of ARDS cases, but mechanisms by which non-pulmonary insults such as extrapulmonary sepsis propagate lung injury remain unclear. Most eukaryotic cells release small anuclear membrane-bound vesicles into the extracellular environment in either physiological or pathophysiological conditions, often called extracellular vesicles (EVs) .Through their cargo containing bioactive molecules such as proteins, mRNAs, and microRNAs and their interaction with target cells, EVs are recognized as important mediators of cellular communication. Mitochondrial contents are clearly present in EVs, and mitochondrial cargo within EVs have been shown to stimulate the production of proinﬂammatory cytokines, further enhancing LPS-induced inﬂammation. Among the mitochondrial contents, mtDNA was present at higher levels in EVs.Therefore, we hypothesis, EVs containing mtDNA play an important role in the occurrence and development of ARDS caused by extrapulmonary sepsis.

Clinical Trial Description

Inclusion criteria: Patients with ARDS caused by abdominal infection Exclusion criteria: age <18 years old or pregnancy; death or discharge within 24 hours after admission; advanced tumor The pathological information of the patients was collected on 24h, 48h after admission including demographic data, Acute Physiology and Chronic Health Evaluation (APACHE) II score , number of organ failures included in the Sequential Organ Failure Assessment (SOFA) score. The levels of lactate and inflammatory mediators (i.e., plasma C-reactive protein and procalcitonin) were detected on 24h and 48h after admission. All patients were followed up for 28 days, and all-cause mortality was recorded. The durations of mechanical ventilation and ICU stay were also recorded. The primary outcome was mortality on Day 28. Secondary outcomes included the ventilator days and ICU length of stay. Peripheral blood samples (2 mL) were collected on 24h and 48h after admission to the ICU. EVs were isolated from the plasma, and mtDNA concentration of plasma DNA was evaluated by RT-qPCR. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05061212
Study type	Observational
Source	Southeast University, China
Contact
Status	Not yet recruiting
Phase
Start date	October 1, 2021
Completion date	December 31, 2022

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06444750` - Comparison of the Proteome in ICU Patients in Search for TRALI Biomarkers
Not yet recruiting	`NCT05306392` - Effects of Induced Moderate Hypothermia on ARDS Patients Under Venovenous ExtraCorporeal Membrane Oxygenation	N/A
Completed	`NCT04274296` - Advisory Lead ARDS Respirator Management
Terminated	`NCT04954014` - Pilot Study of Single Dose Bevacizumab as Treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients	Phase 2
Completed	`NCT04719182` - Practice of Adjunctive Treatments in Intensive Care Unit Patients With COVID-19
Recruiting	`NCT03215316` - Screening Expiratory Flow Limitation by Flow-time Curve	N/A
Recruiting	`NCT04115514` - Treatment of ARDS With Instilled T3	Phase 2
Completed	`NCT05693051` - Use of Prone Position Ventilation in Danish Patients With COVID-19 Induced Severe ARDS Treated With VV-ECMO
Not yet recruiting	`NCT04556864` - Hemodynamic Impact on Critical Care Patients With Lung Damage Secondary to COVID-19
Recruiting	`NCT04174014` - Optimal PEEP Titration Combining Transpulmonary Pressure Measurement and Electric Impedance Tomography	N/A
Enrolling by invitation	`NCT06164639` - Potential Biomarkers for Reflux Aspiration-induced Lung Injury.
Terminated	`NCT05384379` - Efficacy and Safety Evaluation of BZ371B in ARDS Patients	Early Phase 1
Completed	`NCT04375735` - London's Exogenous Surfactant Study for COVID19	Phase 1/Phase 2
Completed	`NCT06224010` - Respiratory Drive and Inspiratory Effort in COVID-19 Associated ARDS
Not yet recruiting	`NCT04530188` - Effects of Sevoflurane on Extravascular Lung Water and Pulmonary Vascular Permeability in Patients With ARDS	Phase 3
Completed	`NCT03405038` - Prone Position Impact in ARDS Patients on the Incidence of Central Venous Catheter Colonization
Recruiting	`NCT05148026` - Regional Citrate Anticoagulation for RRT During V-V ECMO	N/A
Recruiting	`NCT04390360` - Smartphone Application for Initiation of Protective Ventilation. Clinical Impact of Instrumental Dead Space Reduction	N/A
Completed	`NCT06197256` - Cardiac Dysfunction in Critically Ill Covid-19 Patients
Completed	`NCT04008225` - Study of the Effects of Bronchoalveolar Lavage Liquid in the ARDS on the Functioning of the Neutrophil Polynuclear System

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

The Mechanism of Extracellular Vesicles Containing Mitochondrial DNA in ARDS Lung Injury Caused by Extrapulmonary Sepsis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms